Gong Xiaoyan, Gui Xien, Zhang Yuxia, Tien Po
Modern Virology Research Center (MVRC), State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.
Zhongnan Hospital, Wuhan University, Wuhan 430072, China.
J Gen Virol. 2006 Jan;87(Pt 1):151-158. doi: 10.1099/vir.0.81335-0.
The human immunodeficiency virus type 1 (HIV-1) epidemic in China is increasing rapidly at an irrepressible rate. It is caused by HIV-1 subtype B' in central China. After the full-length genome sequencing of the Henan isolate was performed, the definition of optimal cytotoxic T-lymphocyte (CTL) epitopes across the Henan isolate genome has become crucial for vaccine design. In this study, by using ELISPOT assays with synthetic peptides corresponding to the sequence of the Henan isolate, the identification and analysis of Gag-specific CTL responses among 28 treated and 26 untreated infected paid blood donors (PBDs) from the Henan and Hubei provinces of China are presented. These studies focused on CTL responses restricted by the human leukocyte antigen (HLA)-A2 and -A11 molecules, two of the most prominent HLA-A alleles in the Chinese population. The results suggested that, in the subgroup analysis, the magnitude of response in the infected treated subgroup [median, 93 spot-forming cells (SFCs) per 10(6) peripheral blood mononuclear cells (PBMCs)] was significantly lower than that in the chronically infected untreated subgroup (median, 221 SFCs per 10(6) PBMCs), and HLA-A2-restricted treated PBDs had a response of a much higher frequency and magnitude than that of HLA-A11-restricted treated PBDs. Moreover, some novel peptides restricted by the HLA-A2 and -A11 molecules were identified.
中国1型人类免疫缺陷病毒(HIV-1)疫情正以不可抑制的速度迅速蔓延。它是由中国中部的HIV-1 B'亚型引起的。对河南分离株进行全长基因组测序后,确定河南分离株基因组中最佳细胞毒性T淋巴细胞(CTL)表位对于疫苗设计至关重要。在本研究中,通过使用与河南分离株序列对应的合成肽进行ELISPOT分析,对来自中国河南和湖北的28名接受治疗和26名未接受治疗的有偿献血感染者(PBD)中的Gag特异性CTL反应进行了鉴定和分析。这些研究聚焦于受人类白细胞抗原(HLA)-A2和-A11分子限制的CTL反应,这是中国人群中最突出的两个HLA-A等位基因。结果表明,在亚组分析中,感染后接受治疗亚组的反应强度[中位数,每10⁶外周血单个核细胞(PBMC)中有93个斑点形成细胞(SFC)]显著低于慢性感染未治疗亚组(中位数,每10⁶ PBMC中有221个SFC),且HLA-A2限制的接受治疗的PBD的反应频率和强度远高于HLA-A11限制的接受治疗的PBD。此外,还鉴定出了一些受HLA-A2和-A11分子限制的新型肽。